Healthcare Global Enterprises Limited Stock Price Today (NSE: HCG)
Fundamental Score
Healthcare Global Enterprises Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Healthcare Global Enterprises Limited share price today is ₹699.30, down 0.72% on NSE/BSE as of 2 September 2026. Healthcare Global Enterprises Limited (HCG) is a Mid-cap company in the Hospital sector with a market capitalisation of ₹9.66K (Cr). The 52-week high for HCG share price is ₹804.65 and the 52-week low is ₹513.30. At a P/E ratio of 424.20x, HCG is currently trading above its industry average P/E of 48.79x. The company has a Return on Equity (ROE) of 1.22% and a debt-to-equity ratio of 0.68.
Healthcare Global Enterprises Limited Share Price Chart — NSE/BSE Historical Performance
Healthcare Global Enterprises Limited share price chart: 9.17% return over the past month. 52-week high ₹804.65, 52-week low ₹513.30.
Healthcare Global Enterprises Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹704.40 | ₹716.55 | ₹695.80 | ₹699.30 | 95.42K (Cr) | |
| ₹735.00 | ₹737.95 | ₹701.50 | ₹704.40 | 2.70L (Cr) | |
| ₹695.60 | ₹775.00 | ₹687.50 | ₹733.30 | 2.64L (Cr) | |
| ₹703.95 | ₹704.90 | ₹693.55 | ₹696.30 | 54.97K (Cr) | |
| ₹707.00 | ₹714.00 | ₹692.30 | ₹699.95 | 1.05L (Cr) | |
| ₹727.00 | ₹727.00 | ₹698.15 | ₹706.15 | 73.82K (Cr) | |
| ₹721.45 | ₹732.00 | ₹715.30 | ₹724.85 | 54.20K (Cr) | |
| ₹725.95 | ₹729.95 | ₹710.10 | ₹718.80 | 85.87K (Cr) | |
| ₹732.00 | ₹734.80 | ₹718.35 | ₹725.95 | 96.29K (Cr) | |
| ₹743.00 | ₹743.00 | ₹728.00 | ₹730.45 | 1.21L (Cr) |
Healthcare Global Enterprises Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹735.00 | ₹737.95 | ₹695.80 | ₹699.30 | -4.86% | |
| ₹684.00 | ₹775.00 | ₹652.60 | ₹733.30 | +7.21% | |
| ₹627.95 | ₹688.20 | ₹617.45 | ₹671.20 | +6.89% | |
| ₹643.80 | ₹655.05 | ₹590.60 | ₹627.10 | -2.59% | |
| ₹579.80 | ₹664.00 | ₹575.60 | ₹637.25 | +9.91% | |
| ₹536.00 | ₹584.85 | ₹516.85 | ₹572.55 | +6.82% | |
| ₹563.00 | ₹587.15 | ₹513.30 | ₹525.20 | -6.71% | |
| ₹591.10 | ₹613.95 | ₹556.50 | ₹572.11 | -3.21% | |
| ₹667.80 | ₹675.00 | ₹567.25 | ₹592.05 | -11.34% | |
| ₹724.25 | ₹745.00 | ₹657.05 | ₹662.00 | -8.60% | |
| ₹747.00 | ₹770.90 | ₹696.95 | ₹730.35 | -2.23% | |
| ₹640.35 | ₹804.65 | ₹630.60 | ₹747.15 | +16.68% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Overvalued cancer play with stretched financials and integration risk; KKR is the only safety net.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Healthcare Global Enterprises (HCG) completed a rights issue of equity shares aggregating to The equity shares commenced trading on BSE and NSE on April 1, 2026. HCG also received a three-week extension for the Vizag Hospital stake acquisition.
CORE STORY (THE REAL GAME)
HCG is a bet on the growing demand for cancer care in India, fueled by rising incidence and under-penetration of quality treatment. KKR's acquisition of a controlling stake signals confidence in this long-term trend.
- Rights issue completed, reducing immediate funding pressure
- Vizag Hospital acquisition on track
- KKR ownership provides stability
- Faster-than-expected integration of Vizag Hospital
- Significant improvement in interest coverage ratio
- New partnerships with international healthcare providers
- High Debt/Equity ratio of 1.92x
- Extremely high P/E of 296.22x vs industry average of 52.84x
- Micro/Small Cap - liquidity risk
FII increased stake by 1.43%, DII increased stake by 5.14%, Promoter increased stake by 1.32%.
Healthcare spending in India is increasing, but rupee depreciation could impact costs.
Acquiring additional 34% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 1.6 billion.
Yes - Free Cash Flow 5Y: ₹571.13 Cr
HCG needs to demonstrate improved profitability and efficient integration of Vizag Hospital in the next 6 months. Failure to do so will expose the stretched valuation.
Primary Thesis Risk
Inability to service debt due to poor profitability will trigger a collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Healthcare Global Enterprises Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Healthcare Global Enterprises Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of HCG across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (19.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (189.89%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (20.22% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹529.39 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
6 factors identified
Below-Average Return on Equity (1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.43%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 424.20x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.25x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Interest Coverage (1.14x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Healthcare Global Enterprises Limited vs Hospital Peers
Peer Comparison - Hospital
Compare Healthcare Global Enterprises Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
42.7/100 | ₹699.30₹699 | ₹9663.25₹9663.25 | 424.20Average 424.2 Average | 1.22%Poor 1.22% Poor | 7.43%Poor 7.43% Poor | 0.68Good 0.7 Good | — — | 20.22%Excellent 20.22% Excellent | 0.00% | |
Apollo Hospitals Enterprise LimitedApollo Hospital... APOLLOHOSP • 508869 | 62.1/100 | ₹8817.00₹8817 | ₹128448.55₹128448.55 | 61.47Average 61.5 Average | 21.95%Excellent 21.95% Excellent | 19.28%Good 19.28% Good | 0.60Good 0.6 Good | 66.81%Excellent 66.81% Excellent | 19.03%Excellent 19.03% Excellent | 0.22% |
Max Healthcare Institute LimitedMax Healthcare ... MAXHEALTH • 543220 | 56.9/100 | ₹1014.40₹1014 | ₹107422.79₹107422.79 | 73.71Average 73.7 Average | 14.33%Average 14.33% Average | 13.43%Average 13.43% Average | 0.32Excellent 0.3 Excellent | — — | 27.30%Excellent 27.30% Excellent | 0.18% |
Fortis Healthcare LimitedFortis Healthca... FORTIS • 532843 | 56.8/100 | ₹916.70₹917 | ₹73687.64₹73687.64 | 70.32Average 70.3 Average | 11.08%Average 11.08% Average | 12.83%Average 12.83% Average | 0.29Excellent 0.3 Excellent | — — | 17.76%Excellent 17.76% Excellent | 0.10% |
Aster DM Quality Care LimitedAster DM Qualit... ASTERDM • 540975 | 37.2/100 | ₹818.00₹818 | ₹71917.90₹71917.90 | 225.67Average 225.7 Average | 9.70%Poor 9.70% Poor | 11.35%Average 11.35% Average | 0.15Excellent 0.2 Excellent | 21.31%Excellent 21.31% Excellent | -11.61%Poor -11.61% Poor | 0.61% |
Narayana Hrudayalaya Ltd.Narayana Hruday... NH • 539551 | 68.3/100 | ₹1803.00₹1803 | ₹41592.95₹41592.95 | 50.96Average 51.0 Average | 19.74%Good 19.74% Good | 14.53%Average 14.53% Average | 1.07Average 1.1 Average | — — | 25.05%Excellent 25.05% Excellent | 0.22% |
Global Health LimitedGlobal Health L... MEDANTA • 543654 | 59.9/100 | ₹1442.70₹1443 | ₹35993.93₹35993.93 | 64.72Average 64.7 Average | 15.15%Good 15.15% Good | 16.85%Good 16.85% Good | 0.30Excellent 0.3 Excellent | — — | — — | 0.04% |
13.9/100 | ₹805.50₹806 | ₹33947.05₹33947.05 | 166.00Average 166.0 Average | 11.01%Average 11.01% Average | 9.35%Poor 9.35% Poor | 1.44Average 1.4 Average | 3.71%Average 3.71% Average | 24.04%Excellent 24.04% Excellent | 0.00% | |
Dr. Agarwal's Health Care LimitedDr. Agarwal's H... AGARWALEYE • 544350 | 48.5/100 | ₹502.60₹503 | ₹15618.15₹15618.15 | 105.26Average 105.3 Average | 6.84%Poor 6.84% Poor | 10.16%Average 10.16% Average | 0.08Excellent 0.1 Excellent | — — | — — | 0.00% |
Rainbow Childrens Medicare LimitedRainbow Childre... RAINBOW • 543524 | 65.5/100 | ₹1458.70₹1459 | ₹15270.28₹15270.28 | 53.51Average 53.5 Average | 17.86%Good 17.86% Good | 18.10%Good 18.10% Good | 0.00Excellent 0.0 Excellent | — — | — — | 0.23% |
60/100 | ₹318.20₹318 | ₹9829.95₹9829.95 | 52.28Average 52.3 Average | 13.41%Average 13.41% Average | 15.25%Good 15.25% Good | 0.33Excellent 0.3 Excellent | — — | — — | 0.07% | |
Top Hospital Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Apollo Hospitals Enterprise Limited share price128448.55 Cr
- Max Healthcare Institute Limited share price107422.79 Cr
- Fortis Healthcare Limited share price73687.64 Cr
- Aster DM Quality Care Limited share price71917.90 Cr
- Narayana Hrudayalaya Ltd. share price41592.95 Cr
Healthcare Global Enterprises Limited PE Ratio History
Historical price-to-earnings ratio for HCG — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹3.14 | ₹662.00 | 210.8x |
| FY 2024 | ₹3.43 | ₹489.15 | 142.6x |
| FY 2023 | ₹2.10 | ₹365.50 | 174x |
| FY 2022 | ₹3.97 | ₹287.45 | 72.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Healthcare Global Enterprises Limited Quarterly Performance
Latest quarterly metrics for HCG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.36%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
189.89%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
20.22%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Healthcare Global Enterprises Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for HCG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Healthcare Global Enterprises Limited Financial Statements
Annual income statement, balance sheet and cash flow for Healthcare Global Enterprises Limited (HCG) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Healthcare Global Enterprises Limited
About HCG (Healthcare Global Enterprises Limited)
Healthcare Global Enterprises Ltd is a leading institution redefining cancer care within its hospital settings. Stepping inside, one encounters a meticulously designed environment,... intended to foster healing and well-being. The advanced infrastructure houses cutting-edge diagnostic and treatment technologies, from high-resolution imaging suites to specialized operating theaters equipped for complex oncological procedures. A palpable sense of hope permeates the air, amplified by the presence of compassionate medical staff who prioritize patient comfort and understanding. The hospital's architecture emphasizes natural light and open spaces, aiming to minimize anxiety and create a welcoming atmosphere for patients and their families navigating challenging circumstances. Art installations and calming color palettes further contribute to a holistic approach that extends beyond mere physical treatment. Beyond the physical infrastructure, HCG hospitals are hubs of medical innovation and expertise. A multidisciplinary team of oncologists, surgeons, radiologists, and support staff collaborate seamlessly to deliver personalized treatment plans tailored to each patient's unique needs. Research and development are integral components of the hospital's ethos, driving the adoption of novel therapies and techniques. Regular training programs ensure that healthcare professionals stay at the forefront of oncological advancements. Emphasis is placed on precision medicine, utilizing advanced genomic testing and molecular diagnostics to optimize treatment effectiveness while minimizing side effects. This commitment to pioneering approaches positions HCG as a center of excellence in cancer care. The patient experience at HCG hospitals extends far beyond the confines of medical procedures. A comprehensive support system is in place to address the emotional, psychological, and social needs of individuals undergoing cancer treatment. Counseling services, support groups, and palliative care are readily available, fostering a sense of community and shared understanding. The hospital emphasizes open communication and patient empowerment, ensuring that individuals are actively involved in their care decisions. Furthermore, nutritional guidance, rehabilitation programs, and survivorship support are integrated into the treatment journey, promoting long-term well-being and improving the quality of life for patients and their families.
Company Details
Key Leadership
HCG Share Price: Frequently Asked Questions
What is the current share price of Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited (HCG) trades at ₹699.30 on NSE and BSE. Market cap ₹9.66K (Cr). Educational data only.
What is the P/E ratio of Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited has a P/E of 424.20x vs industry average 48.79x.
What is the Bull Run score for Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited has a Bull Run score of 42.7/100 based on 25+ financial parameters.
Does Healthcare Global Enterprises Limited pay dividends?
Healthcare Global Enterprises Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited has ROE of 1.22%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Healthcare Global Enterprises Limited?
Healthcare Global Enterprises Limited has debt-to-equity of 0.68.
Is Healthcare Global Enterprises Limited a good investment?
Bull Run gives Healthcare Global Enterprises Limited a score of 42.7/100. This is not investment advice — consult a SEBI-registered advisor.